- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:36 | Ernexa Therapeutics Inc.: Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND | 89 | GlobeNewswire (Europe) | Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed... ► Artikel lesen | |
| Di | Ernexa Therapeutics Inc.: Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy | 1 | GlobeNewswire (USA) | ||
| 17.09. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors | 162 | GlobeNewswire (Europe) | Dr. Spiegel brings decades of global clinical development, regulatory and oncology leadership experience, including former Chief Medical Officer roles at Schering-Plough and PTC Therapeutics Appointment... ► Artikel lesen | |
| 16.09. | Ernexa Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.09. | Ernexa reports preclinical data for ERNA-201, refocuses on oncology | 1 | Investing.com | ||
| 15.09. | Ernexa meldet präklinische Daten für ERNA-201 und legt Fokus auf Onkologie | 2 | Investing.com Deutsch | ||
| ERNEXA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.09. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing | 262 | GlobeNewswire (Europe) | ERNA-201 demonstrated encouraging disease-modifying activity in the industry-standard collagen-induced arthritis model, providing meaningful proof-of-concept for Ernexa's engineered synthetic iMSC... ► Artikel lesen | |
| 10.08. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage | 1.139 | GlobeNewswire (Europe) | Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governance Appointment further... ► Artikel lesen | |
| 06.08. | Ernexa Therapeutics Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 24.07. | Ernexa Therapeutics Inc.: Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies | 1 | GlobeNewswire (USA) | ||
| 15.07. | Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy | 1 | Benzinga.com | ||
| 15.07. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry | 290 | GlobeNewswire (Europe) | Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Significantly Strengthening Confidence as Company Advances Toward IND ERNA-101 Plus Anti-PD-1 Achieved... ► Artikel lesen | |
| 14.07. | Ernexa Therapeutics Inc.: Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026 | 1 | GlobeNewswire (USA) | ||
| 26.06. | Ernexa Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.06. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients | 1 | GlobeNewswire (USA) | ||
| 17.06. | Ernexa treibt Zelltherapie voran: Klinische Studie für dieses Jahr geplant | 3 | Investing.com Deutsch | ||
| 17.06. | Ernexa advances cell therapy toward clinical trial this year | 3 | Investing.com | ||
| 17.06. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study | 876 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease... ► Artikel lesen | |
| 09.06. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer | 2 | GlobeNewswire (USA) | ||
| 27.05. | Ernexa Therapeutics treibt IND-Antrag für Zelltherapie-Kandidaten ERNA-101 für Q3 voran | 1 | Investing.com Deutsch |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 3,450 | +1,47 % | PTA-AFR: Biofrontera AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Biofrontera AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Biofrontera... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,251 | +4,58 % | Defence Therapeutics Inc.: Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors | Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| TRAWS PHARMA | 0,632 | +9,22 % | Traws Pharma, Inc.: Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights | Advancing tivoxavir marboxil toward MHRA resubmission in Q3 2026 with a revised toxicology package, supporting initiation of the Phase 2a human influenza Challenge studyCompleted the April 2026 private... ► Artikel lesen | |
| CURIS | 0,721 | +1,12 % | Curis, Inc. Announces Pricing of $5.6 Million Public Offering | LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally... ► Artikel lesen | |
| GENPREX | 3,000 | +4,17 % | Genprex, Inc.: Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy | Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials
AUSTIN, Texas, Aug. 18, 2026... ► Artikel lesen | |
| TVARDI THERAPEUTICS | 0,990 | -13,16 % | Tvardi meldet präklinische Daten zu STAT3-Inhibitor bei Kolitis | ||
| NEOVACS | 0,200 | +48,15 % | XFRA NEW INSTRUMENTS AVAILABLE ON 23.06.2026 | The following instruments on XETRA do have their first trading 23.06.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 23.06.2026
Aktien
1 CNE100007CW0 Shenzen Xunce Technology... ► Artikel lesen | |
| ALAUNOS THERAPEUTICS | 0,943 | -7,59 % | Alaunos Therapeutics, Inc.: Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study | This statistical finding supports a lower liver-weight signal after adjustment for body fat percentage, suggesting the finding was not fully explained by measured body fat in this modelLiver-weight... ► Artikel lesen | |
| MARKER THERAPEUTICS | 0,820 | -2,38 % | H.C. Wainwright reiterates Marker Therapeutics stock rating at buy | ||
| AINOS | 1,260 | -5,26 % | Ainos, Inc.: Ainos Completes VELDONA Technology Transfer, Triggering $600,000 License Payment | Partner's Written Confirmation Fulfills Payment Conditions; Initial License Fee Payable Within 15 Business Days HOUSTON, TX / ACCESS Newswire / September 30, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW)... ► Artikel lesen | |
| MATINAS BIOPHARMA | 2,700 | +8,87 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 25.09.2026 | Das Instrument 0FF BMG9156K1018 2020 BULKERS LTD DL 1 EQUITY wird ex Kapitalmassnahme gehandelt am 25.09.2026 The instrument 0FF BMG9156K1018 2020 BULKERS LTD DL 1 EQUITY is traded ex capital adjustment... ► Artikel lesen | |
| ENVERIC BIOSCIENCES | 1,430 | -4,03 % | Morning Market Movers: Huachen AI Parking, FatPipe, Enveric Biosciences, Akanda See Big Swings | TEL AVIV (dpa-AFX) - At 8:00 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 3,580 | -0,28 % | Neuphoria Therapeutics, Inc.: Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc | Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination BURLINGTON, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria"... ► Artikel lesen | |
| SCINAI IMMUNOTHERAPEUTICS LTD | 1,380 | -2,13 % | Scinai Immunotherapeutics Ltd. - F-1, Registration statement for certain foreign private issuers | ||
| CLEARMIND MEDICINE | 0,800 | +1,57 % | Neurothera Labs Inc (2): Neurothera makes patent applications with Clearmind |
ERNEXA THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,090 (-2,62 %) liegt der Kurs bei 3,350 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ERNEXA THERAPEUTICS INC finden Sie auf Wallstreet Online.